Rhythm Pharmaceuticals, Inc.

NasdaqGM:RYTM Stock Report

Market Cap: US$6.4b

Rhythm Pharmaceuticals Future Growth

Future criteria checks 5/6

Rhythm Pharmaceuticals is forecast to grow earnings and revenue by 68.6% and 44% per annum respectively. EPS is expected to grow by 67.8% per annum. Return on equity is forecast to be -36.1% in 3 years.

Key information

68.6%

Earnings growth rate

67.78%

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate44.0%
Future return on equity-36.05%
Analyst coverage

Good

Last updated20 Aug 2025

Recent future growth updates

Recent updates

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Jul 10

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%

Jul 10
Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%

Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?

Jun 25
Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?
User avatar

Label Expansion And Global Healthcare Will Widen Future Market Opportunities

Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

May 04
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Apr 08

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 19
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Rhythm Pharmaceuticals: A Key Year Ahead

Dec 06

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Sep 23
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Sep 22

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 29

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Earnings and Revenue Growth Forecasts

NasdaqGM:RYTM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202753984498310
12/31/2026299-126-108-6414
12/31/2025186-192-173-13213
6/30/2025156-188-108-108N/A
3/31/2025137-174-114-113N/A
12/31/2024130-265-154-114N/A
9/30/2024113-262-165-124N/A
6/30/2024102-261-169-128N/A
3/31/202492-274-182-140N/A
12/31/202377-185-142-136N/A
9/30/202362-186-146-141N/A
6/30/202344-182-164-159N/A
3/31/202334-181-161-156N/A
12/31/202224-181-174-173N/A
9/30/202217-181-173-180N/A
6/30/202213-176-166-173N/A
3/31/20225-166-160-166N/A
12/31/20213-70-139-146N/A
9/30/20211-62-135-135N/A
6/30/20210-60-122-122N/A
3/31/20210-56-120-119N/A
12/31/2020N/A-134-122-122N/A
9/30/2020N/A-132-125-125N/A
6/30/2020N/A-134-132-132N/A
3/31/2020N/A-146-130-127N/A
12/31/2019N/A-141-126-123N/A
9/30/2019N/A-133-115-112N/A
6/30/2019N/A-115-99-95N/A
3/31/2019N/A-87N/A-82N/A
12/31/2018N/A-74N/A-62N/A
9/30/2018N/A-59N/A-49N/A
6/30/2018N/A-53N/A-40N/A
3/31/2018N/A-47N/A-34N/A
12/31/2017N/A-38N/A-29N/A
9/30/2017N/A-36N/A-28N/A
6/30/2017N/A-32N/A-24N/A
3/31/2017N/A-30N/A-24N/A
12/31/2016N/A-29N/A-23N/A
9/30/2016N/A-27N/A-21N/A
6/30/2016N/A-23N/A-18N/A
3/31/2016N/A-17N/A-13N/A
12/31/2015N/A-12N/A-7N/A
9/30/2015N/A-6N/A-4N/A
6/30/2015N/A-3N/A-4N/A
3/31/2015N/A-5N/A-6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RYTM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).

Earnings vs Market: RYTM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RYTM is expected to become profitable in the next 3 years.

Revenue vs Market: RYTM's revenue (44% per year) is forecast to grow faster than the US market (9.6% per year).

High Growth Revenue: RYTM's revenue (44% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RYTM is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/14 17:34
End of Day Share Price 2025/09/12 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rhythm Pharmaceuticals, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Whitney IjemCanaccord Genuity
Jonathan WollebenCitizens JMP Securities, LLC